生长抑素联合乌司他丁治疗重症急性胰腺炎患者的临床效果  

Clinical Effect of Somatostatin Combined with Ulinastatin in the Treatment of Patients with Severe Acute Pancreatitis

作　　者：田野 刘高 刘会勇 孙志祥 TIAN Ye;LIU Gao;LIU Huiyong;SUN Zhixiang(Chongqing Kaizhou District People's Hospital,Chongqing 405400,China;不详)

机构地区：[1]重庆市开州区人民医院,重庆405400

出　　处：《中外医学研究》2023年第20期145-149,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究生长抑素联合乌司他丁治疗重症急性胰腺炎(SAP)患者的临床效果。方法:选取2020年1月—2022年6月重庆市开州区人民医院收治的90例SAP患者为研究对象。根据随机数表法将其分为对照组和试验组,各45例。两组入院后均给予内科一般治疗。对照组给予注射用生长抑素,试验组在对照组基础上给予乌司他丁注射液。比较两组临床疗效,治疗前及治疗7 d后炎症因子,时间指标及不良反应。结果:试验组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗7 d后,两组超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)水平均下降,试验组hs-CRP、IL-6、IL-8、TNF-α水平均明显低于对照组,差异有统计学意义(P<0.05)。试验组腹痛消失时间、腹胀消失时间、肠鸣音恢复时间及血淀粉酶恢复正常时间均早于对照组,差异有统计学意义(P<0.05)。试验组不良反应发生率高于对照组,但差异无统计学意义(P>0.05)。结论:生长抑素联合乌司他丁治疗SAP患者临床效果良好,能够促进患者炎症反应消退,加快症状消失,安全性好。Objective:To explore the clinical effect of Somatostatin combined with Ulinastatin in the treatment of patients with severe acute pancreatitis(SAP).Method:A total of 90 SAP patients admitted to Chongqing Kaizhou District People's Hospital from January 2020 to June 2022 were selected as the study objects.According to the method of random number table,they were divided into control group and experimental group,45 cases in each group.Both groups were given general internal medicine treatment after admission.The control group was given Somatostatin for Injection,and the experimental group was given Ulinastatin Injection based on the control group.The clinical efficacy,inflammatory factors before treatment and after 7 d of treatment,time indexes and adverse reactions were compared between the two groups.Result:The total effective rate of experimental group was higher than that of control group,and the difference was statistically significant(P<0.05).After 7 d of treatment,the levels of hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in both groups were decreased,and the levels of hs-CRP,IL-6,IL-8 and TNF-αin the experimental group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).The disappearance time of abdominal pain,abdominal distension,intestinal sound recovery time and blood amylase recovery time in the experimental group were earlier than those in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was higher than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion:Somatostatin combined with Ulinastatin has good clinical effect in the treatment of SAP patients,which can promote the regression of inflammation reaction in patients,accelerate the disappearance of symptoms,and has good safety.

关 键 词：重症急性胰腺炎 生长抑素 乌司他丁 

分 类 号：R576[医药卫生—消化系统]